Latest From Anthem Inc.
Manufacturers will face the “biggest PBM ever” in price negotiations for pharmacy benefit drugs as a result of the collaboration between the two pharmacy benefit managers.
Start with the trial’s primary objective and then figure out which RWD sources could help inform that outcome, experts say at Duke-Margolis meeting; however, design and underlying objectives of Novo Nordisk’s real-world use of trial of Ozempic have the FDA’s Robert Temple suggesting success will be a ‘longshot.’
Pharmaceutical companies can struggle to understand the business opportunities presented by the federal segment, in part due to perceptions of low profit margins and overwhelming regulatory hurdles that are required to do business in this market. As companies begin to reframe the value of the federal market, it is important to establish context from a global revenue perspective.
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
- Therapeutic Areas
- Anthem Inc.
- WellPoint Inc.
- North America
- Parent & Subsidiaries
- Anthem Inc.
- Senior Management
Joseph R Swedish, Pres. & CEO
Wayne S DeVeydt, EVP & CFO
Craig Sammitt, MD, EVP & Chief Clin. Officer
- Contact Info
Phone: (317) 488-6000
120 Monument Cir.
Indianapolis, IN 46204
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.